Experimental injection aims to tackle root cause of rare liver disease
NCT ID NCT03946449
Summary
This small, early-stage study tested an investigational drug called fazirsiran in people with liver disease caused by Alpha-1 antitrypsin deficiency. Sixteen participants received multiple injections under the skin to see if the drug could safely reduce the harmful protein that builds up in the liver. Researchers measured changes in liver protein levels, scarring, and inflammation over 24 to 48 weeks.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALPHA 1-ANTITRYPSIN DEFICIENCY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Research Center 1
Vienna, 1090, Austria
-
Research Center 1
Aachen, 52074, Germany
-
Research Center 2
Edinburgh, EH19 3BJ, United Kingdom
-
Research Center 3
Cambridge, CB2 0QQ, United Kingdom
Conditions
Explore the condition pages connected to this study.